Malignant cancer cell uncontrolled growth depends on the persistent nutrient availability such as glucose and amino acids, which is required for cancer cell energetic and biosynthetic pathways. As a nuclear hormone receptor, peroxisomeproliferator-activated receptor δ (PPARδ) plays a critical role in inflammation and cancer, however, it is still unclear the regulatory mechanism of PPARδ on cancer cell metabolism. Here, we found that PPARδ directly regulated neutral amino acid transporter SLC1-A5 (solute carrier family 1 member 5) and glucose transporter-1 (Glut1) gene transcription, leading to uptake of glucose and amino acid, activation of mTOR signaling, and tumor progression. In contrast, silence of PPARδ or its antagonist inhibited this event. More importantly, PPARδ promoted cancer cell metabolic reprogramming resulting in chemoresistance, which was alleviated by PPARδ antagonist. These findings revealed a novel mechanism of PPARδ-mediated tumor progression, which provided a potential strategy for cancer treatment.
Introduction
Uncontrolled malignant cell growth and proliferation depends on rapid and robust nutrient availability such as glucose and amino acids, which is required for biosynthesis of macromolecules such as lipids, proteins and nucleic acids (1) . Cancer cell can alter the glucose and glutamine metabolism by metabolic reprogramming (mutation in MYC and IDH1) resulting in fueling cancer cell growth and malignancy (1) (2) (3) (4) . Oncogenic K-Ras induces Glut-1 expression and glucose uptake resulting in anabolic glucose metabolism (4) . In addition, K-Ras-mediated Glut1 expression leading to increased glucose uptake and cell survival in low-glucose conditions (5) , suggesting that cancer cell promotes metabolic reprogramming in the solid harsh tumor environment. Furthermore, K-Ras decouples glutamine and glucose metabolism to maintain cancer cell growth, which promotes glutamine carbon into biosynthesis of macromolecules (6) . c-Myc increases mitochondrial gene expressions, biogenesis and glutaminolysis (7, 8) . c-Myc can induce lactate dehydrogenase-A gene (LDH-A) expression with increasing in anaerobic glycolysis (9) . On the other hand, as a nuclear receptor, PPARδ is the ligand-activated transcription factor. Activated PPARδ heterodimerizes with retinoid X receptors (RXRs) leading to binding peroxisome-proliferator response element (PPRE: AGGTCA N AGGTCA) to regulate the target gene expressions, which is involved in obesity, diabetes, atherosclerosis, inflammation and cancer (10) (11) (12) (13) . However, the mechanism of PPARδ on cancer cell metabolic signaling is still unclear. Here we found that PPARδ directly regulated the gene expressions of Glut1 and SLC1-A5 leading to increased cancer cell metabolism and tumor growth.
Materials and methods

Cell culture and reagents
The human HCT-116, SW480, Hela and MCF-7 cells were obtained from the ATCC in 2014. The cell lines have been tested and authenticated. SW480 PPARδ −/− cells were developed by CRISP/Cas-9 method. These cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Gibco), Protease inhibitor cocktail (Sigma), Geneticin (G418 sulfate, Thermo Scientific) and Cisplatin (Tokyo Chemical industry).
Plasmids and shRNA
Human PPARδ cDNA was subcloned into pcDNA3 vector. Plasmids were transfected by turboFect transfection reagent according to the manufacturer's instructions (Thermo Scientific). PPARδ, Glut1 and SLC1-A5 shRNA plasmids (GV248 vector) were purchased from GeneCHEM (China).
Western blot and antibodies
Actin, GAPDH, mTOR, p-MTOR, S6K, p-S6K, 4EBP1, p-4EBP1, PPARδ, Glut1, Glut4 and SLC1-A5 were purchased from Sangon Biotech (Shanghai, China). Secondary antibodies were obtained from Jackson Immunoresearch. The samples were subjected to SDS-PAGE, transferred to a nitrocellulose membrane, then probed by Western blot analysis with the indicated antibody and developed by using an ECL reagent.
Real-time PCR
Total RNA was isolated by using RNeasy kit (Sangon Biotech) and assayed by using real-time PCR assay kit (Takara). Relative mRNA expression levels were normalized against β-actin. Fold change over control was determined according to the ΔCt method. Glut1 primers: Forward: 5ʹ-CAATGCTGATGATGAACCTGCTGG-3ʹ, reverse:
5ʹ-GAACACCTGGGCGATGAGGATG-3ʹ; SLC1-A5: Forward: 5ʹ-TGTCAGCAGCCTTTCGCTCATAC-3ʹ, reverse:5ʹ-GCAAACACTACCAAGCCCAGGAT-3ʹ. β-actin primers: Forward: 5ʹ-GGTGGGCATGGGTCAGAAGGAT-3ʹ, reverse 5ʹ-CACACGCAGCTCATTGTAGAAGGT-3ʹ.
ChIP analysis
Expressed PPARδ SW480 cells or GSK0660 treated SW480 cells were added 1% formaldehyde to crosslink DNA-protein complex for 10 min at room temperature. After that, the final concentration of 0.125 M glycine was added to stop the reaction, and then washed with cold phosphate-buffered saline. Cells were lysated in buffer (10 mM Tris-HCl, pH 8.0, 85 mM KCl, 0.5% NP40, 5 mM EDTA, 0.25% triton and 1× proteinase inhibitor), and then sonicated DNA to 200-500 bp DNA fragments. Agarose beads with PPARδ antibody or IgG control was added into the lysates for overnight. After that, beads were washed, eluted, reversed cross-linking. DNA was assayed by PCR using the following primers: Glut1 forward: CTCAGTGGCTCACGCCTGTAAT, reverse: CCTCCCGAGTAGCTGGGATTACA; SLC1-A5 forward: GCTTCTGACATTACCACTAC, reverse: TTCCTTACTCCA CCTGACA.
Electrophoretic mobility shift (EMSA)/gel-shift analysis
Human PPARδ or RXRα cDNA was subcloned into PGEX-4P-1 vector, respectively. GST-PPARδ or GST-RXRα was expressed in E.coli strain BL21(DE3) [pAPlacIQ] . The recombinant proteins were purified using glutathione beads. A DNA probe containing PPARδ binding regions for Glut1 or SLC1-A5 was labeled with biotin by terminal deoxynucleotidyl transferase (TdT) using an EMSA probe biotin labeling kit (Beyotime, GS008). Glut1 probes: Forward: AGGTGGGTGGATCACGAGGTCAAGAGTTCA, reverse: TGAACTCTTGACC TCGTGATCCACCCACCT; SLC1A5 probes: Forward: AGCCTGAAATGTCAC AGAACAGGCTAGAG, reverse: CTCTAGCCTGTTCTGTGACATTTCAGGCT. The DNA-protein binding reaction was performed using Chemiluminescent EMSA kit (Beyotime, GS009) according to manufacturer's instruction. 0.2 µg PPARδ antibody was added into the reaction for supershift assay. After incubation for 30 min at room temperature, the reactions were assayed by naïve PAGE and developed by ECL reagent.
Luciferase assay
The Glut1 or SLC1-A5 promoter sequence was subcloned into PGL3-Basic vector at KpnI site, respectively. Glut1 primers: forward:
ATTTCTCTATCGATAGGTACCGCTACTACGGAGGCTAAGGTGG, reverse:
CACGCGTAAGAGCTCGGTACCGCTGTAAGGCAAGCTGGGATG; SLC1A5 primers: Forward: ATTTCTCTATCGATAGGTACCCAACA CTCAAGGCGGTATGACTTAT, Reverse: CACGCGTAAGAGCTCGGTACCGCGG AAGCTGCCAGGGATAA. Glut1 mutant Forward: AGAGTTCAAGACC AGCCTGGCC; Glut1 mutant Reverse: ACCCACCTCGCCTCCCAAAGTA. SLC1-A5 mutant Forward: GGCTAGAGATGGGAAAGGAATGAGGA; SLC1-A5 mutant Reverse: TTCAGGCTTTCATGCTTGCTCAAAGA. WT or PPARδ knockout SW480 cells were transfected with the indicated plasmids together with pRL-TK for 36h. After that, cell lysates were assayed by using a dual luciferase reporter assay system (Promega). In some experiments, cells were treated with PPARδ antagonist as indicated prior to luciferase reporter assay.
Glucose consumption, lactate production assay
Cells were plated into 96-well plates and grown in DMEM (5.5 mmol/l glucose) containing 10% fetal bovine serum with some wells left blank. After the cells reached confluence, the medium was removed and the same fetal bovine serum DMEM was added to all wells including the blank wells. After incubation for 12 h, the medium was removed and its glucose concentrations were determined by the glucose oxidase method (Applygen). Lactate production was measured by colorimetric assay (Goybio). Total glucose consumption and lactate production were calculated by subtracting from values for a mediumonly blank well incubated for the same amount of time at 37°C. Cell number was determined by trypan blue exclusion assay for normalization.
l-glutamine uptake analysis
For l-glutamine uptake analysis, amino acid starvation was performed by depriving cells of fetal bovine serum for 20 h and then incubated with D-phosphate-buffered saline containing CaCl 2 , MgCl 2 , 15mg/l phenol red, 20 mM HEPES and 1 g/l d-glucose (starve medium) for 3 h. Starved cells were cultured with DMEM containing 4 mM L-glutamine for 45 m. Further, the cells were washed twice with ice-cold phosphate-buffered saline, and intracellular glutamine levels were measured using the L-glutamine Assay kit (Goybio) and normalized to total protein levels.
Soft agar and cell proliferation analysis
SW480 cells were transfected with pcDNA3 or PPARδ plasmids respectively; cells were selected with G418. Stable PPARδ expressing SW480 cell lines were seeded into 60-mm cell culture dish in 0.3% Noble agar. After 2 weeks, dishes were stained with 0.05% crystal violet for 2 h at room temperature and colonies were counted in the entire dish. Cell numbers were counted by trypan blue exclusion assay. Cell proliferation was assayed by using MTT method.
Xenograft mice model
NU/NU nude mice were purchased from SLAC Laboratory Animal Corporation (Shanghai). Stable PPARδ expressing SW480 cells were injected subcutaneously in nude mice and after 4 weeks, tumor volume was measured with a digital caliper. WT or PPARδ −/− SW480 cells were injected subcutaneously in nude mice. After 4 weeks, tumor volume was measured with a digital caliper. In other studies, SW480 cells were injected subcutaneously in nude mice. After 2 weeks, mice were treated without or with GSK0660 (20 mg/kg/day) or GSK0660 + cisplatin (3 mg/kg) for another 2 weeks by intraperitoneal injection. Tumor volume = 1/2(length × width 2 ).
Statistical analysis
Data are expressed as the mean ± SEM. Differences between two dependent groups were evaluated with the paired Student's t-test. Comparisons among multiple groups were performed with one-way ANOVA followed by Dunnett's tests. All P-values were two-tailed, and P < 0.05 was accepted as being statistically significant.
Abbreviations
DMEM
Dulbecco's modified Eagle's medium EMSA electrophoretic mobility shift FBS fetal bovine serum PPARδ peroxisome-proliferator-activated receptor δ RXR retinoid X receptor
Results
PPARδ promotes the gene transcription activity of Glut1 and SLC1-A5
SW480 cells were transfected with PPARδ plasmids. The results show that PPARδ increased Glut1 and SLC1-A5 protein levels ( Figure 1A ). In contrast, PPARδ −/− SW480 cells reduced the protein levels of Glut1 and SLC1-A5 ( Figure 1B ). Further analysis shows that overexpression of PPARδ increased the gene and protein levels of Glut1 and SLC1-A5 in different cancer cell lines ( Figure 1C, Supplementary  Figure 1A , available at Carcinogenesis Online). Consistent with this, PPARδ knockout or silenced cells decreased the gene and protein levels of Glut1 and SLC1A-5 ( Figure 1D, Supplementary Figure 1B , available at Carcinogenesis Online). These findings show that PPARδ regulated gene and protein expressions of Glut1 and SLC1-A5. We next detected whether PPARδ could increase the transcription activity of Glut1 and SLC1-A5. Luciferase analysis shows that PPARδ significantly enhanced Glut1 and SLC1-A5 transcription activity ( Figure 1E ), which was inhibited in PPARδ −/− SW480 cells ( Figure 1F ), suggesting that PPARδ-mediated Glut1 and SLC1-A5 expressions involved in enhancing their gene transcriptions.
PPARδ directly regulates the gene transcription of Glut1 and SLC1-A5
We have demonstrated that PPARδ promoted the gene transcription of Glut1 and SLC1-A5 resulting in increased the protein levels, while the mechanism was unclear. As well known, PPARs/ RXRs bind to the PPRE of targeted gene promoter regions. PPRE motif includes AGGTCA N AGGTCA consensus sequence (14, 15) . Alignment analysis shows that the promoter region of Glut1 or SLC1-A5 contains one similar PPRE motif (Figure 2A ), which was identified by using PPRE mutant of Glut1 or SLC1-A5. The results show that PPARδ did not increase the activity of Glut1 or SLC1-A5 by using the PPRE mutant ( Supplementary Figure 2A and B, available at Carcinogenesis Online). ChIP analysis shows that PPARδ directly targeted the gene promoter regions of Glut1 or SLC1-A5 ( Figure 2B ). To further detect whether PPARδ could directly bind to the predicted PPRE motif of Glut1 and SLC1-A5, EMSA analysis was performed. The results show that PPARδ significantly bound to the PPRE motif region of Glut1 and SLC1-A5 ( Figure 2C ). These findings suggest that PPARδ directly regulated the gene transcription activity of Glut1 and SLC1-A5 by binding to the promoter regions.
PPARδ increases metabolic signaling
Glucose and amino acids are the main nutrient sources for cancer cell growth, which are required for biosynthesis of macromolecules such as lipids, proteins and nucleic acids (1) . In this process, Glut1 and SLC1-A5 are the major membrane transporters for the uptake of glucose and amino acids (1, 16) . As expectedly, our results show that PPARδ increased SW480 or Hela cancer cells glucose consumption, lactate production Glucose and amino acids influx leads to mammalian target of rapamycin (mTOR) activation (17) . mTOR is a serine/threonine protein kinase, which plays a critical role in regulation of cell homeostasis in response to environmental stress such as glucose, amino acids and growth factors (17) . mTOR inhibits the eukaryotic translation initiation factor 4E binding protein (4EBP1) activity by inducing it phosphorylation resulting in regulation of the translation of 5ʹcapped mRNA (18) . mTOR can induce the phosphorylation of ribosomal protein S6 kinase (S6K) leading to regulation of the eukaryotic initiation factor 3 (eIF3) translation complex (19) . The results show that PPARδ activated mTOR signaling by inducing phosphorylation of mTOR, S6K and 4EBP1 ( Figure 3G ). In contrast, PPARδ knockout cells reversed this event ( Figure 3H ). More importantly, silenced Glut1 and SLC1-A5 reduced mTOR signaling activation (Supplementary Figure 4 , available at Carcinogenesis Online). These results suggest that PPARδ-mediated the expression of Glut1 and SLC1-A5 promoted the influx of glucose and amino acids, leading to mTOR signaling activation.
PPARδ-mediated metabolic signaling promotes tumor progression
Glut1 and SLC1-A5 play a critical role in accelerating the influx of glucose and amino acids to support tumor cell growth and proliferation (1) (2) (3) (4) 6) . To detect whether PPARδ-mediated cancer cell proliferation was dependent on Glut1 and SLC1-A5, PPARδ-overexpressing SW480 cells were transfected with Glut1 and SLC1-A5 shRNA plasmids alone or in combination. The results show that silenced Glut1 and SLC1-A5 in SW480 cells inhibited PPARδ-mediated cell proliferation (Supplementary Figure 5 , available at Carcinogenesis Online) and reversed cancer cell cisplatin chemoresistence induced by PPARδ (Supplementary Figure 6 , available at Carcinogenesis Online). In contrast, overexpression of Glut1 and SLC1-A5 in the PPARδ knockout SW480 cells promoted cell proliferation (Supplementary Figure 7, available at Carcinogenesis Online). These findings suggest that Glut1 and SLC1-A5 contributed to PPARδ-mediated cancer cell proliferation. Further analysis shows that overexpression of PPARδ increased cancer cell proliferation ( Figure 4A ), tumor growth ( Figure 4B ) and tumor weight ( Figure 4C ), which was associated with increased the expressions of Glut1 and SLC1-A5, mTOR activation ( Figure 4D ). In contrast, PPARδ knockout inhibited tumor growth and tumor weight ( Figure 4E and F) , which was involved in the suppression of Glut1 and SLC1-A5 ( Figure 4G ). These findings suggest that PPARδ-mediated the expressions of Glut1 and SLC1-A5 led to mTOR activation and tumor progression.
PPARδ antagonist inhibits tumor progression and increases chemotherapy sensitivity
As a nuclear hormone receptor, PPARδ is the ligand-activated transcription factor. Activated PPARδ heterodimerizes with RXRs resulting in gene expression (10-13). Our results showed Online). Further analysis shows that GSK0660 suppressed mTOR activation (Supplementary Figure 11 , available at Carcinogenesis Online). Similarly, GSK0660 suppressed tumor growth ( Figure 5A ) and tumor weight ( Figure 5B ), which was involved in inhibition of Glut1 and SLC1-A5 expression ( Figure 5C ). Glutamine uptake activates mTOR activation resulting in chemoresistance (20) . Further analysis shows that GSK0660 enhanced cisplatin-mediated inhibition of tumor growth ( Figure 5D ) and tumor weight ( Figure 5E ), suggesting that inhibition of PPARδ-mediated metabolic signaling increased cancer cell chemotherapy sensitivity.
Discussion
In this study, our results demonstrated that the Glut1 and SLC1-A5 were the direct targets of PPARδ by enhancing their gene transcription activity and expressions, leading to influx of glucose and amino acids, which promoted mTOR activation and tumor progression. As one of the GLUT family members, Glut1 is widely expressed in most types of cancer cells that plays an important role in glucose uptake for cancer cell growth and proliferation (21, 22) . Glucose metabolism is one of the hallmarks of cancer cells, which is required for biosynthesis of macromolecules (1). In addition, glutamine is the most abundant free amino acid and important nitrogen source for synthesis of macromolecules for cancer cell growth, which is regulated by membrane glutamine transporters (23) . SLC1-A5 is one of the important glutamine transporters in regulation of essential amino acid influx (24) , which promotes tumor progression. Depletion of SLC1-A5 abolishes tumor progression (20) . Consistent with this, our results show that silenced Glut1 and SLC1-A5 inhibited PPARδ-mediated cell proliferation and increased cisplatin sensitivity. To maintain cancer cell growth, they facilitate metabolic reprogramming by alteration of metabolic signaling pathway (1) (2) (3) (4) . Increasing evidences show that PPARδ promotes tumorigenesis by multiple pathways (15, 25) , however, it is still unclear the mechanism of PPARδ on cancer cell metabolism. Here we found that PPARδ directly targeted the gene promoter regions of Glut1 and SLC1-A5 leading to increased their gene and protein expressions, which promoted influx of glucose and amino acids that is required for cancer cell biosynthesis of macromolecules (1) . Overexpressing K-Ras or K-Ras mutation could enhance Glut1 expression resulting in glucose uptake and process of anabolic glucose metabolism (4, 5) . Our results show that PPARδ antagonist GSK0660 inhibited the expressions of Glut1 and SLC1-A5, which was in a PPARδ-dependent manner. More importantly, GSK0660 enhanced chemotherapy reagent cisplatin sensitivity to cancer cells, suggesting that PPARδ is a potential drug target for cancer treatment. However, it is unclear whether these effects were mediated by K-Ras mutation or not, which needs to be further determined. Our results demonstrated that PPARδ directly induced the expressions of Glut1 and SLC1-A5, subsequently, enhanced the influx of amino acids. Amino acids influx leads to activation of mammalian target of rapamycin (mTOR) (17) . mTOR is a serine/threonine protein kinase, which is a master regulator of cell homeostasis between growth and autophagy in response to environmental stress such as glucose, amino acids, and growth factors (17) . Activation of mTOR induces the downstream 4EBP1 and S6K signaling protein phosphorylation and regulation of gene transcription (18, 19) . Moreover, both the glucose and glutamine influx can activate mTOR pathway resulting in cell proliferation and survival (17, 20) . Although ligand-activated PPARδ/mTOR signaling mediates mammary neoplasia (26) , other report shows that PPARδ activation elicits mammary tumorigenesis by Akt not mTOR signaling (27) . Our results show that silence of Glut1 and SLC1-A5 abolished PPARδ-mediated mTOR signaling activation, suggesting that PPARδ-mediated mTOR signaling was dependent on influx of glucose and amino acids. More importantly, silence of Glut1 and SLC1-A5 inhibited PPARδ-mediated cancer cell proliferation. Taken together, PPARδ directly triggered the gene expressions of Glut1 and SLC1-A5, subsequently, promoted influx of glucose and amino acid resulting in mTOR activation and tumor progression. In contrast, PPARδ antagonist reversed this event leading to increased cancer cell sensitivity to chemotherapy drug ( Figure 5F ).
